top of page
TranspariMED logo

European Medicines Agency takes multiple steps to improve clinical trial reporting

2 hours ago
3 min read

Europe’s medicines regulator has started to deliver on its recent promises to improve the reporting of clinical trial results.

 

In May 2026, a TranspariMED blog discussed an academic study showing that half of all clinical trials of medicines in Europe were violating a new transparency law. In June, a coalition of 20 health groups wrote to the European Medicines Agency urging it to take action. In July, EMA responded by announcing a range of measures to improve trial reporting.

 

Several recent moves indicate that EMA has been working hard to fix the problem.

 

1. Transparency about missing trial results

 

As promised, EMA has now started publishing Key Performance Indicators that track how many clinical trial results are made public in a quarterly newsletter.


The latest data show that overall, less than 10% of due clinical trials are currently missing results.

 

 

EMA’s choice of performance indicators is revealing.

 

EMA could have tried to evade accountability by adopting a meaningless metric like “number of results published,” which would have revealed nothing about the success of regulators’ efforts to improve compliance.

 

Instead, EMA chose a meaningful metric. Going forward, everyone will be able to track whether the proportion of trial results that are reported on time goes up or down. This strongly indicates that EMA wants to keep improving on the status quo.

 

What EMA does not reveal (yet) is how reporting rates vary by country. This would give citizens insight into how successful the 30 different national medicines regulators across Europe are at promoting and enforcing compliance with the law. EMA and national regulators have access to those data, but EMA has not publicly released them (yet).

 

Another thing that EMA does not (yet) disclose is whether the results uploaded contain all elements set out by law. Previous research has shown that many “results” documents lack basic outcome data. It seems likely that EMA does not (yet) monitor the quality of results submitted – so those data probably do not exist (yet).

 

2. Sending reminders to sponsors


A recently published slideshow throws light on how EMA communicates with sponsors about their obligation to make trial results public.

 

Sponsors receive multiple reminders before, when, and after results must be uploaded for one of their trials (see below). These reminders are routinely and automatically sent through the CTIS registry. Since this summer, sponsors can choose to additionally receive reminders by email.

 

National medicines regulators are also kept up to date on the trials they are responsible for. This is crucial because national regulators are responsible for actually enforcing the law. (A few months ago, one national regulator told TranspariMED that they could not identify overdue trial results. EMA has now fixed that problem.)

 

 

As the image above shows, EMA's reminder system (still) lacks an escalation procedure.

 

When a company or university fails to make a trial result public in violation of the law, it will receive several reminders. But if that sponsor continues to fail to make the results public, EMA follow-up is limited to annual reminders.

 

Going forward, this system could be further strengthened. For example, the very first day a sponsor breaks the law, EMA could automatically send it a formal letter by mail. This would likely further improve compliance rates, and thereby also reduce the downstream enforcement burden for national regulators.

 

3. Clarity on what needs to be reported


EMA recently updated and expanded a Q&A document for trial sponsors with more details about reporting rules.

 

Importantly, the document clarifies regulatory expectations for reporting the results of trials that were terminated early (spoiler alert: it’s complicated).

 

The document also provides useful guidance on complex cases, such as whether and how to upload the results of sub-studies, intermediate data analyses, and interim results, and explains what data within results documents can be redacted.

 

Is EMA overstating reporting rates?

 

A Polish nonprofit is running a very detailed dashboard that tracks clinical trial activity and results reporting across the entire European CTIS registry.

 

For example, it provides a breakdown of the reporting performance of individual trial sponsors:

 

 

The dashboard looks impressive, but the compliance rates it displays are significantly lower than those stated by EMA (see further above).

 

The dashboard’s data may not be robust. Precisely assessing compliance with reporting rules requires access to data on deadline extensions granted to sponsors. Those data are not (yet) publicly displayed on the CTIS registry.

 

TranspariMED has reached out to the Polish team, requesting more information on the dashboard methodology. Keep an eye on this blog for future updates.

 
 
 

Comments


Subscribe
Subscribe
Recent Posts
bottom of page